Scarica l'app Stockscreener
0.842
0.23%
0.0019
Dopo l'orario di chiusura:
.84
-0.002
-0.24%
Precedente Chiudi:
$0.8401
Aprire:
$0.82
Volume 24 ore:
7,494
Relative Volume:
0.07
Capitalizzazione di mercato:
$10.12M
Reddito:
-
Utile/perdita netta:
$-15.42M
Rapporto P/E:
-0.4576
EPS:
-1.84
Flusso di cassa netto:
$-13.41M
1 W Prestazione:
-11.37%
1M Prestazione:
-7.37%
6M Prestazione:
-60.65%
1 anno Prestazione:
-52.96%
Intervallo 1D:
$0.82
$0.8944
Intervallo di 1 settimana:
$0.82
$0.962
Portata 52W:
$0.81
$3.10
Indaptus Therapeutics Inc Stock (INDP) Company Profile
Nome
Indaptus Therapeutics Inc
Settore
Industria
Telefono
(646) 427-2727
Indirizzo
3 COLUMBUS CIRCLE, NEW YORK
Confronta INDP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INDP
Indaptus Therapeutics Inc
|
0.842 | 10.12M | 0 | -15.42M | -13.41M | -1.84 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Indaptus Therapeutics Inc Borsa (INDP) Ultime notizie
Indaptus Therapeutics looks to raise $2.25M in private placement - MSN
Indaptus Therapeutics Announces $2.25 Million Private Placement - Defense World
Indaptus Therapeutics, Inc. announced that it expects to receive $2.246493 million in funding - Marketscreener.com
Indaptus Therapeutics, Inc. Announces $2.25 Million Private Placement Priced At-The-Market Under Nasdaq Rules - The Manila Times
Indaptus Therapeutics Secures $2.25M Private Placement for R&D Advancement - StockTitan
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - The Manila Times
Indaptus Therapeutics Provides Year-End Review and Outlook for 2025 - GlobeNewswire Inc.
Indaptus Therapeutics (NASDAQ:INDP) Trading Up 6.3% – Still a Buy? - Defense World
INDP stock touches 52-week low at $0.81 amid market challenges - Investing.com Canada
Viracta stock falls on strategic review (VIRX:NASDAQ) - Seeking Alpha
Indaptus Therapeutics files to sell 1.94M shares of common stock - MSN
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World
Gram-negative bacteria platform offers multiple immune receptor agonists for tumor immunotherapy - BioWorld Online
Indaptus Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Indaptus Therapeutics announces $2.135M registered direct offering - MSN
Indaptus secures $2.1 million through stock and warrants sale By Investing.com - Investing.com Canada
Indaptus secures $2.1 million through stock and warrants sale - Investing.com India
Indaptus Therapeutics Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - citybiz
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement - The Manila Times
Indaptus Therapeutics Secures $2.1M Direct Offering with Insider Participation | INDP Stock News - StockTitan
Maxim Group Has Lowered Expectations for Indaptus Therapeutics (NASDAQ:INDP) Stock Price - Defense World
Indaptus Therapeutics Inc (INDP) Quarterly 10-Q Report - Quartz
Indaptus Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology - The Manila Times
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting - The Manila Times
Indaptus' Decoy20 Shows Promise: Phase 1 Trial Reports Safe Weekly Dosing in Cancer Study | INDP Stock News - StockTitan
Invention and characterization of a systemically administered, attenuated and killed bacteria-based multiple immune receptor agonist for anti-tumor immunotherapy - Frontiers
Rx Rundown: Opella, Samsung Biologics, Dimension and more - MM+M Online
Indaptus Therapeutics to Present at Two Upcoming Investor Conferences - The Manila Times
Indaptus Therapeutics partners with BeiGene for cancer study By Investing.com - Investing.com Canada
Indaptus Therapeutics Shares Rise After Pact to Develop Cancer Treatment - Morningstar
Indaptus Therapeutics partners with BeiGene for cancer study - Investing.com
Indaptus Therapeutics Announces Clinical Supply Agreement - GlobeNewswire
Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations - The Manila Times
Indaptus Therapeutics, Inc. Enters into Clinical Supply Agreement with Beigene Switzerland GmbH - Marketscreener.com
Provident Bank's First-Time Home Buyer Survey Reveals That While Homeownership Continues to Be Challenging, Many Americans Are Finding Their Home in Less Than a Year - The Manila Times
Indaptus Therapeutics Initiates Unrestricted Enrollment of - GlobeNewswire
Indaptus Therapeutics Initiates Unrestricted Enrollment of Patients on Decoy20 Weekly Dosing Based on Encouraging Safety Data - Investing.com
Indaptus Therapeutics (INDP) Price Target Increased by 25.00% to 10.20 - MSN
Indaptus Therapeutics Founder and Chief Scientific Officer - GlobeNewswire
Indaptus Therapeutics to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit - The Manila Times
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Increases By 140.5% - Defense World
Cybin (NYSEAMERICAN:CYBN) Shares Down 4.4% - Defense World
Japan Tobacco Inc. (OTCMKTS:JAPAY) Short Interest Update - Defense World
Sei Investments Co. Has $17.72 Million Position in Teradata Co. (NYSE:TDC) - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Stock Price Down 9.2% - Defense World
Intelligent Bio Solutions Inc. Reports Fiscal 2024 Fourth Quarter and Full Year Financial Results and Operational Highlights - Marketscreener.com
Kaskela Law LLC Announces Shareholder Investigation of Integra LifeSciences Holdings Corp. (NASDAQ: IART) and Encourages Long-Term IART Shareholders to Contact the Firm - Business Wire
The Escalator: Imre, Kyverna Therapeutics, The Bloc and more - MM+M Online
StockNews.com Downgrades Independent Bank (NASDAQ:INDB) to Sell - Defense World
Indaptus Therapeutics Inc Azioni (INDP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):